Bell's News
Feb 25, 2025
Bell Therapeutics Secures CE MDR Certification for Neuroscience-Based DTx
Bell Therapeutics, a neuroscience-based digital healthcare startup, announced on the 26th that its insomnia digital therapeutic, Sleep Thera, has obtained the European Union (EU) medical device certification, CE MDR.
Oct 7, 2024
Bell Therapeutics Joins 'ECHOH' Consortium for Dementia and Hearing Loss
Bell Therapeutics, a startup focused on developing brain science-based digital therapeutics, announced on the 7th that it has partnered with the research consortium "ECHOH" (Enhancing Cognitive Health through Optimal Hearing) to conduct joint research aimed at improving hearing and cognitive health.
Aug 8, 2024
Bell Therapeutics Obtains GMP Certification for Medical Device Software Manufacturing
The neuroscience-based digital therapeutics startup Bell Therapeutics announced on the 8th that it has received a Good Manufacturing Practice (GMP) certification from the Ministry of Food and Drug Safety for meeting medical device manufacturing and quality management standards.
May 23, 2024
Auditory Rehabilitation DTx by Bell Therapeutics: Collaboration with SNU Hospital
The neuroscience-based digital therapeutics (DTx) startup Bell Therapeutics announced on the 23rd that it has signed an agreement with the Cochlear Implant Center at Seoul National University Hospital to supply a hearing rehabilitation application (app).
May 13, 2024
Bell Therapeutics, a Breakthrough from the Neuroscience and Music Integration
According to industry estimates, around 60 million people globally suffer from severe hearing loss that requires cochlear implant surgery. Severe hearing loss, classified as the inability to hear sounds below 70 decibels, means individuals may not hear a doorbell or knock in a quiet home.